PE20100241A1 - Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico - Google Patents
Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilicoInfo
- Publication number
- PE20100241A1 PE20100241A1 PE2010000134A PE2010000134A PE20100241A1 PE 20100241 A1 PE20100241 A1 PE 20100241A1 PE 2010000134 A PE2010000134 A PE 2010000134A PE 2010000134 A PE2010000134 A PE 2010000134A PE 20100241 A1 PE20100241 A1 PE 20100241A1
- Authority
- PE
- Peru
- Prior art keywords
- peaks
- presents
- chlorosaliciloyl
- sodium salt
- crystalline
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000055006 Calcitonin Human genes 0.000 abstract 1
- 108060001064 Calcitonin Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
- 229960004015 calcitonin Drugs 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 150000004689 octahydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
REFERIDA A LAS FORMAS CRISTALINAS I, II, II Y IV DE LA SAL DE DI-SODIO DEL ACIDO N-(5-CLOROSALICILOIL)-8-AMINOCAPRILICO, DONDE LA FORMA I CORRESPONDIENTE AL MONOHIDRATO CRISTALINO PRESENTA UN PATRON DE DIFRACCION DE POLVO DE RAYO X CON PICOS DE 7.5, 10.4, 14.2, 15.0, 15.5, 16.1, 18.4, 20.8, 23.6, 24.1, 24.5, 24.8, 25.4, 26.6, 27.2, 27.5, 29.6 Y 31.5; LA FORMA II CORRESPONDIENTE AL SOLVATO CRISTALINO PRESENTA PICOS 7.5, 14.1, 16.5, 18.5, 25 Y 26; LA FORMA III CORRESPONDIENTE AL OCTAHIDRATO CRISTALINO PRESENTA PICOS DE 4.8, 10.4, 11.7 Y 14.6; LA FORMA IV PRESENTA PICOS DE 7.2, 18.2 Y 24.7. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION DE LA FORMA CRISTALINA I Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL POLIMORFO CRISTALINO I, II, II O IV Y UN AGENTE ACTIVO TAL COMO CALCITONINA, INSULINA O UNA HORMONA DE CRECIMIENTO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71882905P | 2005-09-19 | 2005-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20100241A1 true PE20100241A1 (es) | 2010-04-16 |
Family
ID=37889458
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001133A PE20070548A1 (es) | 2005-09-19 | 2006-09-18 | Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico |
| PE2010000134A PE20100241A1 (es) | 2005-09-19 | 2006-09-18 | Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001133A PE20070548A1 (es) | 2005-09-19 | 2006-09-18 | Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8026392B2 (es) |
| EP (1) | EP1937627A4 (es) |
| JP (1) | JP2009508875A (es) |
| KR (1) | KR20080049128A (es) |
| CN (2) | CN101627011A (es) |
| AR (1) | AR058053A1 (es) |
| AU (1) | AU2006292337B8 (es) |
| BR (1) | BRPI0616558B1 (es) |
| CA (1) | CA2619673C (es) |
| GT (1) | GT200600421A (es) |
| IL (1) | IL189015A (es) |
| JO (1) | JO3684B1 (es) |
| NZ (1) | NZ566397A (es) |
| PE (2) | PE20070548A1 (es) |
| RU (1) | RU2507196C2 (es) |
| SG (1) | SG165397A1 (es) |
| TW (1) | TWI386386B (es) |
| WO (1) | WO2007035718A2 (es) |
| ZA (1) | ZA200803206B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0603252D0 (en) * | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
| US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| BRPI0716261A2 (pt) * | 2006-08-31 | 2013-08-06 | Novartis Ag | composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral |
| JP5985985B2 (ja) | 2009-08-03 | 2016-09-06 | エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． | 胃腸への影響が減少した即効型ナプロキセン組成物 |
| SG10202011046RA (en) | 2012-09-21 | 2020-12-30 | Intensity Therapeutics Inc | Method of treating cancer |
| KR102901689B1 (ko) * | 2020-05-29 | 2025-12-22 | 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 | 칼륨 n-[8-(2-히드록시벤조일)아미노]옥타노에이트결정 다형체 및 이의 제조 방법과 용도 |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
| IL307875A (en) * | 2021-04-22 | 2023-12-01 | Civi Biopharma Inc | Oral administration of oligonucleotides |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1234561A (en) | 1985-06-26 | 1988-03-29 | Kenneth M. White | Profiled body roller-reamer stabilizer |
| US5069419A (en) | 1989-06-23 | 1991-12-03 | Ic Sensors Inc. | Semiconductor microactuator |
| US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| JPH11140064A (ja) * | 1997-11-10 | 1999-05-25 | Nippon Nohyaku Co Ltd | １，２，３−チアジアゾール誘導体の製造方法及び中間体化合物 |
| US6126140A (en) | 1997-12-29 | 2000-10-03 | Honeywell International Inc. | Monolithic bi-directional microvalve with enclosed drive electric field |
| AU3378100A (en) * | 1999-02-26 | 2000-09-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CA2369591C (en) * | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
| EP1535625B1 (en) * | 1999-04-05 | 2014-01-08 | Novartis AG | Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin |
| UA74539C2 (en) * | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
| US7049283B2 (en) | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| ATE356631T1 (de) | 2001-06-01 | 2007-04-15 | Novartis Pharma Gmbh | Orale verabreichung von parathyroidhormon und calcitonin |
| WO2003015822A1 (en) | 2001-08-17 | 2003-02-27 | Novartis Ag | 5-cnac as oral delivery agent for parathyroid hormone fragments |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TW200403052A (en) * | 2002-07-17 | 2004-03-01 | Novartis Ag | Use of organic compounds |
| TWI307279B (en) * | 2002-08-01 | 2009-03-11 | Novartis Ag | Oral administration of calcitonin |
| JP3924616B2 (ja) | 2003-06-30 | 2007-06-06 | 独立行政法人物質・材料研究機構 | 微小サイズの温度感知素子を用いる温度計測方法 |
| KR20060105735A (ko) | 2003-07-04 | 2006-10-11 | 니코메드 덴마크 에이피에스 | 경구용 부갑상선 호르몬 함유 약학 조성물 |
| WO2005004900A1 (en) * | 2003-07-11 | 2005-01-20 | Novartis Ag | Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form |
| WO2005014031A1 (en) | 2003-07-23 | 2005-02-17 | Novartis Ag | Use of calcitonin in osteoarthritis |
| WO2006124047A2 (en) * | 2004-08-13 | 2006-11-23 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| EP1793819A2 (en) | 2004-09-23 | 2007-06-13 | Wyeth a Corporation of the State of Delaware | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
| GB0427603D0 (en) * | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| GB0427600D0 (en) * | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| US20070048725A1 (en) | 2005-08-25 | 2007-03-01 | Arrington Ben O'mar | Machine perfusion of tissue grafts for transplantation |
| ES2523857T3 (es) | 2005-08-25 | 2014-12-02 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Modelo de carcinogénesis por fusión de células madre |
-
2006
- 2006-09-18 SG SG201006791-6A patent/SG165397A1/en unknown
- 2006-09-18 JP JP2008531430A patent/JP2009508875A/ja active Pending
- 2006-09-18 EP EP06814934A patent/EP1937627A4/en not_active Ceased
- 2006-09-18 WO PCT/US2006/036455 patent/WO2007035718A2/en not_active Ceased
- 2006-09-18 CN CN200680034457A patent/CN101627011A/zh active Pending
- 2006-09-18 PE PE2006001133A patent/PE20070548A1/es not_active Application Discontinuation
- 2006-09-18 BR BRPI0616558-3A patent/BRPI0616558B1/pt not_active IP Right Cessation
- 2006-09-18 AR ARP060104079A patent/AR058053A1/es not_active Application Discontinuation
- 2006-09-18 RU RU2008103699/04A patent/RU2507196C2/ru active
- 2006-09-18 NZ NZ566397A patent/NZ566397A/en not_active IP Right Cessation
- 2006-09-18 KR KR1020087009540A patent/KR20080049128A/ko not_active Ceased
- 2006-09-18 CA CA2619673A patent/CA2619673C/en active Active
- 2006-09-18 PE PE2010000134A patent/PE20100241A1/es not_active Application Discontinuation
- 2006-09-18 CN CN201610060265.XA patent/CN105641686A/zh active Pending
- 2006-09-18 US US12/067,239 patent/US8026392B2/en active Active
- 2006-09-18 AU AU2006292337A patent/AU2006292337B8/en not_active Ceased
- 2006-09-18 TW TW095134448A patent/TWI386386B/zh not_active IP Right Cessation
- 2006-09-19 GT GT200600421A patent/GT200600421A/es unknown
- 2006-09-19 JO JOP/2006/0324A patent/JO3684B1/ar active
-
2008
- 2008-01-24 IL IL189015A patent/IL189015A/en active IP Right Grant
- 2008-04-11 ZA ZA200803206A patent/ZA200803206B/xx unknown
-
2011
- 2011-08-11 US US13/207,750 patent/US8431736B2/en active Active
-
2013
- 2013-04-05 US US13/857,643 patent/US9238074B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20130142A7 (es) | Preparación de gadobutrol de alta pureza | |
| GT199900203A (es) | Composiciones de celecoxib. | |
| ECSP066535A (es) | Composiciones y formas de dosis para absorcion mejorada de gabapentina y pregabalina | |
| AR025428A1 (es) | Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asicomo eventualmente otros excipientes | |
| CL2011000170A1 (es) | Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa. | |
| UY33984A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas | |
| BRPI0819319B8 (pt) | análogos de aminoglicosídeo antibacteriano | |
| CR9556A (es) | Complejo ingrediente activo estable de sales del acido-o-acetilsalicilico con aminoacidos basicos y glicina | |
| CL2012000446A1 (es) | Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios. | |
| CR11441A (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
| BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
| NZ593524A (en) | A nonapeptide with anti-tumour activity | |
| PE20100241A1 (es) | Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico | |
| MY165041A (en) | Composition for improving brain function and method for improving brain function | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| CL2007003120A1 (es) | Uso de una cantidad terapeuticamente eficaz de compuestos derivados de acido carbamico sustituidos y otro agente activo, para el tratamiento de la depresion. | |
| NI200700031A (es) | Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas | |
| AR071774A1 (es) | Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso. | |
| ATE549016T1 (de) | Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe | |
| PL1795186T3 (pl) | Preparat leku zawierający flupirtynę o kontrolowanym uwalnianiu substancji czynnej | |
| AR026704A1 (es) | Forma cristalina | |
| RU2006131594A (ru) | Гликозидное пролекарство 5-аминосалициловой кислоты | |
| AR062215A1 (es) | Inhibidor de trombina activo por via oral | |
| UY27472A1 (es) | Metodo para la preparación de una composición farmacéutica que comprende un acido-5-amino-salicilico, para uso en el tratamiento de la colitis ulcerosa y enfermedad de crohn. | |
| UY28427A1 (es) | Composicion farmacéutica como forma de dosificación sólida y método para su fabricación |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |